Media Contact:
Hans Danneels
+1 510 287 6314
[email protected]
Twitter: @byteflies

  • Highly specialized Byteflies wearables used in UCB monitoring project for epileptic seizures
  • To accelerate growth, Byteflies closes first investment round of $600,000

San Francisco, Calif., August 16, 2017 – Byteflies, the Belgian-American start-up company, and aspirational leader in wearable health solutions, is partnering with the biopharmaceutical company UCB to monitor difficult to measure seizures experienced by people with epilepsy.

This collaboration with UCB, global leader in the field of research and development of medicines to support the management of epilepsy, is an important step forward for Byteflies, and builds on a recent successful funding round from a group of American and Belgian investors which raised $600,000.

Byteflies has the ambition to become the reference in wearable health solutions. With a unique toolkit of specialized wearables, and an accompanying data platform, Byteflies is targeting the pharmaceutical industry, start-ups and research groups.

The company aims to continue their momentum and aspires towards rapid growth. Before the end of this year, Byteflies plans to launch its very own wearable health toolkit which, by harnessing the company’s unique wearable technology, can dramatically accelerate clinical trials and research.

Currently, unique Byteflies wearables are being used in a monitoring project for UCB. As part of a consortium, which includes UCB, the University of Leuven, the Leuven University Hospital and product developer PiliPili, Byteflies is providing discreet and accurate monitoring of difficult to measure seizures in a test group of patients.

“In partnership with Byteflies, UCB is excited to be at the forefront of next generation wearables, collaborating to evaluate the benefits of measuring patient symptoms and experiences which, in the future, could support individually tailored care approaches” says Erik Janssen, VP, Head of Innovative Solutions, Neurology Patient Value Unit, UCB. “Everything we do at UCB is Inspired by patients, and Driven by science. In this regard, harnessing technology and innovation are crucial elements in our mission to provide maximum value to those patients who need it the most”.

Byteflies recently raised $600,000 in capital from a group of private investors in the United States and in Belgium. “We are very pleased with this funding, which will not only give us the necessary resources to grow, but also provides us with the expertise of our investors to lead our company towards the next step,” explains Hans Danneels, CEO and co-founder of Byteflies.

Byteflies is confident in its technology solutions, and believes its tools will contribute towards modern and connected healthcare environments by providing continuous and precise measurements needed to build personalized approaches to patient care.

Headquartered in Belgium, Byteflies sits at the center of pharmaceutical innovation, with a strong Belgian tradition in the field of clinical research. Its second office, located in Silicon Valley, operates in the heart of digital innovation.


Facebook Comments